Skip to main content
OpenTrials
Completed

NCT Number: NCT03289871

Clinical Evaluation of the Efficacy of a Medical Device in Treatment of Toenail Onychomycosis

This study evaluates the effect of the medical device "Excilor® Fungal Nail Infection" in the treatment of toenail onychomycosis. Half of the participants will receive the tested product and the other half will receive a comparator (Amorolfin 5%). Patients will be followed during 6 months.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Onychomycosis Bacterial Infections and Mycoses Dermatomycoses Infections Mycoses Nail Diseases Skin Diseases Skin Diseases, Infectious Skin and Connective Tissue Diseases Tinea

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital Habib Thameur, Tunis, Tunisia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject having given her/his informed, written consent,
  • Subject cooperative and aware of the modalities of use and the necessity and duration of the controls so that perfect adhesion to the protocol can be expected.
  • Subject being psychologically able to understand information and to give their/his/her consent.
  • Age: more than 18 years.
  • Subject with superficial onychomycosis on at least one great toenail or light to moderate disto-lateral onychomycosis (without matrix involvement and involvement <2/3 of the tablet).
  • Subject with positive results of KOH staining.
  • Subject having stopped any systemic antifungal treatment since at least 6 months before inclusion and/or any topical antifungal treatment since at least 3 months before inclusion.
  • Female subjects of childbearing potential should use an accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after the study end.

Exclusion criteria

  • Subject considered by the Investigator likely to be non-compliant with the protocol.
  • Patient enrolled in another clinical trial during the test period.
  • Woman being pregnant, nursing or planning a pregnancy during the course of this study.
  • Subject having a known allergy to one of the constituents of the tested products.
  • Patient suffering from serious or progressive diseases (to investigator's discretion), such as diabetes, peripheral circulatory disease, HIV, psoriasis, lichen planus, immunosuppressive pathology….
  • Subject with cutaneous pathology on studied zone (other than onychomycosis like angioma, dermatitis…).

Treatment and study plan

Excilor

Device

Loceryl 5%

Drug

Primary outcomes

  1. At the end of the study (day 168), evolution of the percentage of healthy surface versus baseline, was evaluated by a blinded investigator. Comparison with the comparator product.

    Time frame: After 168 days of treatment

    Percentage healthy surface was assessed using digital image analysis. Briefly, two macro-photographs (top and front) were made of the great toenail, placed beside a piece of graph paper to allow determination of the exact size of the nail during analysis (contour tracing). Consequently, all pictures were digitalised and recorded on the computer. Image analysis of the top picture was performed with Adobe Photoshop software. For each photograph, a blinded dermatologist traced the healthy surface.

Secondary outcomes

  1. At different time points, evolution of the percentage of healthy surface versus baseline, was evaluated by a blinded investigator. Comparison with the comparator product.

    Time frame: After 14, 28, 56 and 112 days of treatment

    Percentage healthy surface was assessed using digital image analysis. Briefly, two macro-photographs (top and front) were made of the great toenail, placed beside a piece of graph paper to allow determination of the exact size of the nail during analysis (contour tracing). Consequently, all pictures were digitalised and recorded on the computer. Image analysis of the top picture was performed with Adobe Photoshop software. For each photograph, a blinded dermatologist traced the healthy surface.

  2. Evaluation of the clinical efficacy assessed by the investigator with structured scales. Comparison with the comparator product.

    Time frame: On Day 0, Day 14, Day 28, Day 56, Day 112 and Day 168

    Onycholysis, nail dystrophy, nail discoloration and nail thickening were assessed using the following scores:

    0 = none, 1 = very slight, 2 = slight, 3 =moderate, and 4 = severe.

  3. Evaluation of the microbiological efficacy of the product assessed by fungal culture and comparison with the comparator product.

    Time frame: On baseline (day zero) and day 168

  4. Evaluation of the product tolerance, assessed by the investigator by clinical evaluation and subject interrogatory with a score from 0 (bad tolerance) to 3 (very good tolerance).

    Time frame: After 14, 28, 56 and 112 days of treatment

  5. Evaluation of the quality of life of the subjects thanks to the questionnaire NailQoL . Comparison with the comparator product.

    Time frame: On Day 0, Day 14, Day 28, Day 56, Day 112 and Day 168

  6. Subjective evaluation by subjects by completing the subjective evaluation questionnaire at each visit.

    Time frame: On Day 0, Day 14, Day 28, Day 56, Day 112 and Day 168

Sponsors and collaborators

Lead sponsor

Oystershell NV

Industry

Registry information

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Sep 21, 2017
Registry last updated
Sep 21, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.